<DOC>
	<DOC>NCT00713921</DOC>
	<brief_summary>Develop and quantify methods for evaluating bladder dysfunction in diabetes and stroke</brief_summary>
	<brief_title>Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Cholinergic Antagonists</mesh_term>
	<criteria>Stroke Population: Ischemic or hemorrhagic stroke in the anterior or posterior circulation within the past month in persons 21 years of age and over NIH Stroke Scale Score of 4 or greater one month poststroke Modified Rankin Scale of 2 or greater Patients with motor or verbal impairment with surrogacy consent Diabetic Population: Clinically stable diabetes type 2 females 21 years of age or older Peripheral neuropathy associated with diabetes Dyck stage 2 or 3 Clinical evaluation by neurologist reveals no other likely cause of neuropathy Stroke Population: Men Patients with cardiac pacemaker or other indwelling device that would preclude neurophysiologic testing; Patients with an indwelling urinary catheter that cannot be removed Patients who are on warfarin or similar anticoagulants that cannot be stopped for the study procedures Patients with a poor prognosis due to stroke or underlying illness who, it is anticipated, would be unable to participate for the period of the study Females with current pregnancy, multiparity &gt;/=4, prior pelvic floor dysfunction, or pelvic floor tumor. Women with incontinence prior to stroke, cystocele, rectocele, or urethral stricture Patients unable to tolerate Detrol LA; such patients would include those with significant renal or hepatic disease, those currently taking drugs metabolized by the cytochrome P450 enzyme system that might confound interpretation of responses ( Delaviridine, indinavir, nelfinavir, ritonavir, amiodarone, aprepitant, cimetidine, ciprofloxacin, clarithromycin, diltiazem, erythromycin, fluconazole, fluvoxamine, grapefruit juice, itraconazole, ketoconazole, mifepristone, nefazodone, norfloxacin, verapamil, efavirenz, nevirapine, carbamazepine, phenobarbital, phenyltoin, rifampin, St. John's wort, troglitazone, oxcarbazepine, pioglitazone, rifabutin); those with urinary retention, gastric retention, uncontrolled narrow angel glaucoma, or those with a known sensitivity to the drug or its ingredients Patients who have a history of diabetes Pregnancy or actively seeking pregnancy Patients who are cognitively impaired Diabetes Population: Men Patients with cardiac pacemaker or other indwelling device that would preclude neurophysiologic testing; Patients with an indwelling urinary catheter that cannot be removed Patients who are on warfarin or similar anticoagulants that cannot be stopped for the study procedures Patients with a poor prognosis due to underlying illness who, it is anticipated, would be unable to participate for the period of the study Females with current pregnancy, multiparity &gt;/=4, prior pelvic floor dysfunction, pelvic floor tumor, cystocele, rectocele, or urethral stricture Patients unable to tolerate Detrol LA; such patients would include those with significant renal or hepatic disease, those currently taking drugs metabolized by the cytochrome P450 enzyme system that might confound interpretation of responses ( Delaviridine, indinavir, nelfinavir, ritonavir, amiodarone, aprepitant, cimetidine, ciprofloxacin, clarithromycin, diltiazem, erythromycin, fluconazole, fluvoxamine, grapefruit juice, itraconazole, ketoconazole, mifepristone, nefazodone, norfloxacin, verapamil, efavirenz, nevirapine, carbamazepine, phenobarbital, phenyltoin, rifampin, St. John's wort, troglitazone, oxcarbazepine, pioglitazone, rifabutin); those with urinary retention, gastric retention, uncontrolled narrow angel glaucoma, or those with a known sensitivity to the drug or its ingredients Pregnancy or actively seeking pregnancy</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Female</keyword>
	<keyword>Diabetics</keyword>
	<keyword>Stroke</keyword>
</DOC>